Egalet is a pharmaceutical company developing, manufacturing and commercializing treatment for pain and other conditions. Co. has two pain products, SPRIX® (ketorolac tromethamine) Nasal Spray and OXAYDO™ (oxycodone HCI, USP) tablets for oral use only-CII, to treat pain. Using its proprietary Guardian™ Technology, Co. has two product candidates in development; ARYMO ER™ (morphine sulfate) extended-release (ER), an ER morphine product formulated with abuse-deterrent (AD) properties, and Egalet-002, an AD, ER, oral oxycodone formulation, which is in a Phase 3 program. Also, Co. has Egalet-003, an AD stimulant product candidate, and Egalet-004, an AD, ER hydrocodone-based product candidate. We show 20 historical shares outstanding datapoints in our coverage of EGLT's shares outstanding history.
Understanding the changing numbers of EGLT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like EGLT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching EGLT by allowing them to research EGLT shares outstanding history
as well as any other stock in our coverage universe. |
Free EGLT Email Alerts:
Video: Shares Outstanding Importance
